ABOUT SIMR
Company Profile
Management Team
SAB
Vision & Mission
Milestones
Investors
R&D
Research Field
Pipeline
Translational Center
MEDIA
Expanded Access Policy
Press Releases
PARTNER
Business Development
Research Cooperation
JOIN US
Career Opportunities-Clinical&RA
Career Opportunities-BD
Career Opportunities-Preclinical
CONTACT
中文
|
EN
ABOUT SIMR
Company Profile
Management Team
SAB
Vision & Mission
Milestones
Investors
R&D
Research Field
Pipeline
Translational Center
MEDIA
Expanded Access Policy
Press Releases
PARTNER
Business Development
Research Cooperation
JOIN US
Career Opportunities-Clinical&RA
Career Opportunities-BD
Career Opportunities-Preclinical
CONTACT
中文
EN
en2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Home
>
ABOUT SIMR
>
Milestones
>
2022
2022
en2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
In June, the first subject administration was completed in the Chinese clinical trial of SR1375
发布时间：2022年11月18日
In June, the first subject administration was completed in the Chinese clinical trial of SR1375
上一篇：In May, SR419, a drug candidate with a novel mechanism of action for the treatment of peripheral neuropathic pain, was granted fast track designation (FTD) by the U.S. Food and Drug Administration (FD
下一篇：In November,SIMR Biotech received 150 million Chinese Yuan C1 round of financing to accelerate product development and commercialization cooperation
